BfArM - Federal Institute for Drugs and Medical Devices

Navigation and service

Information Letter on Trobalt® (retigabine): worldwide withdrawal

Active substance: retigabin

The company GlaxoSmithKline GmbH & CO KG is sending out information that as of the end of June 2017, all strengths of the medicinal product Trobalt® (retigabine) will be discontinued on a worldwide level and will thus cease to be available. The medicinal product was already withdrawn from the German market on 1 July 2012. However, based on company information, several patients in Germany are still being treated with imported products from other European countries which is why physicians in Germany will also be circulating the corresponding information.

Download DHPC / Information letter , Download_VeroeffentlichtAm_EN PDF, 103KB, File is accessible

Use of cookies

Cookies help us to provide our services. By using our website you agree that we can use cookies. Read more about our Privacy Policy and visit the following link: Privacy Policy (only in German)

OK